Abramov D, Kobo O, Mamas MA (2024) Association of Cardiovascular Health Metrics and Mortality Among Individuals With and Without Cancer. J Am Heart Assoc 13:e032683. https://doi.org/10.1161/JAHA.123.032683

Article  PubMed  PubMed Central  Google Scholar 

Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, Senthivel N, Asavisanu K, Obeid M, Tripodaki ES, Angelis V, Fleming E, Goode EF, John S, Rosen SD, Allen M, Stanway S, Lyon AR, Ring A (2021) Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res 188:149–163. https://doi.org/10.1007/s10549-021-06192-w

Article  CAS  Google Scholar 

Buehning F, Lerchner T, Vogel J et al (2024) Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol 119:1–15. https://doi.org/10.1007/s00395-024-01070-0

Article  CAS  Google Scholar 

Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C, Lamendola P, Tinti L, Teofili L, Hohaus S, Lanza GA, Ferdinandy P, Varga Z, Crea F, Lombardo A, Minotti G (2024) Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01059-9

Article  PubMed  Google Scholar 

Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P, Rodríguez IR, Gómez Prieto P, Buño Soto A, Canales Albendea M, Albaladejo A, Mediavilla G, Feliu Batlle J, Rodríguez Fraga O, Martínez Monzonis A, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, González-Juanatey JR, López-Sendón J, CARDIOTOX registry investigators (2022) Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol 29:859–868. https://doi.org/10.1093/eurjpc/zwaa034

Article  PubMed  Google Scholar 

Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, Lang NN, Oudit GY, Touyz RM, American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on the Kidney in Cardiovascular Disease (2023) Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 80:e46–e57. https://doi.org/10.1161/HYP.0000000000000224

Article  CAS  PubMed  Google Scholar 

Cronin M, Crowley A, Davey MG, Ryan P, Abdelshafy M, Elkoumy A, Elzomor H, Arsang-Jang S, Ganly S, Nash P, Crowley J, Sharif F, Simpkin A, Lowery A, Wijns W, Kerin M, Soliman O (2023) Heart failure association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer. J Clin Med 12:1278. https://doi.org/10.3390/jcm12041278

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ (2019) Cancer and heart disease: associations and relations. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1539

Article  PubMed  Google Scholar 

Efentakis P, Choustoulaki A, Kwiatkowski G et al (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol 119:1–12. https://doi.org/10.1007/s00395-024-01046-0

Article  CAS  Google Scholar 

Fuster JJ (2021) Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thromb Res 206:143–151. https://doi.org/10.1016/j.thromres.2021.12.009

Article  CAS  Google Scholar 

Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Agüero J, Fernández-Jiménez R, Martín-García A, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez PL, Fuster V, Sánchez-González J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779–791. https://doi.org/10.1016/j.jacc.2018.11.046

Article  PubMed  Google Scholar 

Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, Molina-Iracheta A, Pérez-Martínez C, García RD, González-Calle D, Lobo M, Sánchez PL, Oliver E, Córdoba R, Fuster V, Sánchez-González J, Ibanez B (2021) Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res 117:1132–1143. https://doi.org/10.1093/cvr/cvaa181

Article  CAS  PubMed  Google Scholar 

Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV (2024) Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01068-8

Article  PubMed  Google Scholar 

Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R (2021) Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 10:947–959. https://doi.org/10.1093/ehjacc/zuab056

Article  PubMed  Google Scholar 

Glen C, Adam S, McDowell K, Waterston A, Tan YY, Petrie MC, Coats CJ, Lang NN (2023) Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores. JACC CardioOncol 5:628–637. https://doi.org/10.1016/j.jaccao.2023.04.004

Article  PubMed  PubMed Central  Google Scholar 

Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C (2020) Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2:270–292. https://doi.org/10.1016/j.jaccao.2020.04.011

Article  PubMed  PubMed Central  Google Scholar 

Heusch G, Rassaf T (2021) Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning? Cardiovasc Res 117:985–986. https://doi.org/10.1093/cvr/cvaa199

Article  CAS  PubMed  Google Scholar 

Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144–e145. https://doi.org/10.1093/cvr/cvad111

Article  CAS  PubMed  Google Scholar 

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O’Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43:280–299. https://doi.org/10.1093/eurheartj/ehab674

Article  PubMed  Google Scholar 

Ibáñez B, Gomes-Silva M (2023) Remote ischemic conditioning for anthracycline cardiotoxicity: the need to protect the most vulnerable. JACC CardioOncol 5:356–359. https://doi.org/10.1016/j.jaccao.2023.05.002

Article  PubMed  PubMed Central  Google Scholar 

Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40:1756–1763. https://doi.org/10.1093/eurheartj/ehy453

Article  PubMed  Google Scholar 

Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, Asteggiano R, Szmit S, Cohen-Solal A, Abdin A, Jurczak W, Garrido Lopez P, Sverdlov AL, Tocchetti CG, Barac A, Parrini I, Zamorano P, Iakobishvili Z, Pudil R, Badimon L, Kirby AM, Blaes AH, Farmakis D, Curigliano G, Stephens R, Lyon AR, Lopez-Fernandez T (2022) European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes 9:1–7. https://doi.org/10.1093/ehjqcco/qcac070

Article  PubMed  PubMed Central  Google Scholar 

Li W, Wang Z, Jiang C, Hua C, Tang Y, Zhang H, Liu X, Zheng S, Wang Y, Gao M, Lv Q, Dong J, Ma C, Du X (2024) Effect of intensive blood pressure control on cardiovascular outcomes in cancer survivors. Hypertension 81:620–628. https://doi.org/10.1161/HYPERTENSIONAHA.123.22194

Article  CAS  PubMed  Google Scholar 

López-Fernández T, Farmakis D, Ameri P, Asteggiano R, de Azambuja E, Aznar M, Barac A, Bayes-Genis A, Bax JJ, Bergler-Klein J, Boriani G, Celutkiene J, Coats A, Cohen-Solal A, Córdoba R, Cosyns B, Filippatos G, Fox K, Gulati G, Inciardi RM, Lee G, Mamas MA, Novo G, Plummer C, Psyrri A, Rakisheva A, Suter T, Tini G, Tocchetti CG, Toutouzas K, Wilhelm M, Metra M, Lyon AR, Rosano GMC (2024) European Society of Cardiology Core Curriculum for cardio-oncology. Eur J Heart Fail 26:754–771. https://doi.org/10.1002/ejhf.3102

Article  PubMed  Google Scholar 

Lopez-Mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, Chen MY, Meyersohn N, Daly R, Slim A, Rochitte C, Blaha M, Whelton S, Dzaye O, Dent S, Milgrom S, Ky B, Iliescu C, Mamas MA, Ferencik M (2023) Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Comput Tomogr 17:66–83. https://doi.org/10.1016/j.jcct.2022.09.002

Article  PubMed  Google Scholar 

López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodríguez Rodríguez I, Rodríguez Fraga O, Albaladejo A, Mediavilla G, González-Juanatey JR, Martínez Monzonis A, Gómez Prieto P, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, López FT (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41:1720–1729. https://doi.org/10.1093/eurheartj/ehaa006

Article